Inhaled Nitric Oxide Improves Outcomes After Successful Cardiopulmonary Resuscitation in Mice

Shizuka Minamishima, MD*; Kotaro Kida, MD, PhD*; Kentaro Tokuda, MD; Huifang Wang, PhD; Patrick Y. Sips, PhD; Shizuko Kosugi, MD; Joseph B. Mandeville, PhD; Emmanuel S. Buys, PhD; Peter Brouckaert, MD, PhD; Philip K. Liu, PhD; Christina H. Liu, PhD; Kenneth D. Bloch, MD; Fumito Ichinose, MD, PhD

**Background**—Sudden cardiac arrest (CA) is a leading cause of death worldwide. Breathing nitric oxide (NO) reduces ischemia/reperfusion injury in animal models and in patients. The objective of this study was to learn whether inhaled NO improves outcomes after CA and cardiopulmonary resuscitation (CPR).

**Methods and Results**—Adult male mice were subjected to potassium-induced CA for 7.5 minutes whereupon CPR was performed with chest compression and mechanical ventilation. One hour after CPR, mice were extubated and breathed air alone or air supplemented with 40 ppm NO for 23 hours. Mice that were subjected to CA/CPR and breathed air exhibited a poor 10-day survival rate (4 of 13), depressed neurological and left ventricular function, and increased caspase-3 activation and inflammatory cytokine induction in the brain. Magnetic resonance imaging revealed brain regions with marked water diffusion abnormality 24 hours after CA/CPR in mice that breathed air. Breathing air supplemented with NO for 23 hours starting 1 hour after CPR attenuated neurological and left ventricular dysfunction 4 days after CA/CPR and markedly improved 10-day survival rate (11 of 13; \( P = 0.003 \) versus mice breathing air). The protective effects of inhaled NO on the outcome after CA/CPR were associated with reduced water diffusion abnormality, caspase-3 activation, and cytokine induction in the brain and increased serum nitrate/nitrite levels. Deficiency of the \( \alpha \)I subunit of soluble guanylate cyclase, a primary target of NO, abrogated the ability of inhaled NO to improve outcomes after CA/CPR.

**Conclusions**—These results suggest that NO inhalation after CA and successful CPR improves outcome via soluble guanylate cyclase–dependent mechanisms. (Circulation. 2011;124:00-00.)

**Key Words:** cardiopulmonary resuscitation ■ heart arrest ■ magnetic resonance imaging ■ nitric oxide synthase ■ physiology

Sudden cardiac arrest (CA) is a leading cause of death worldwide.1 Despite advances in cardiopulmonary resuscitation (CPR) methods, including the introduction of the automatic electric defibrillator and therapeutic hypothermia,2,3 <8% of adult out-of-hospital CA victims survive to hospital discharge,4 and up to 60% of survivors have moderate to severe cognitive deficits 3 months after resuscitation.5 The poor outcome after CA is due at least partly to the post-CA syndrome, which includes neurological and myocardial dysfunction and systemic inflammation. Although therapeutic hypothermia has proved effective in clinical studies,2,3 no pharmacological agent is available to improve outcomes of post-CA syndrome.

Clinical Perspective on p 000

Nitric oxide (NO) is produced from NO synthases (NOS1, NOS2, and NOS3). One of the primary targets of NO is soluble guanylate cyclase (sGC), which generates the second messenger cGMP on activation. sGC is a heme-containing heterodimeric enzyme composed of 1 \( \alpha \) and 1 \( \beta \) subunit. In most tissues, including heart, lung, and vascular smooth muscle cells, the sG\( \alpha \)1\( \beta \)1 heterodimer is the predominant isoform. NO exerts a number of effects that would be expected to prevent ischemia/reperfusion (IR) injury, including inhibition of reactive oxygen species–producing enzymes and direct scavenging of reactive oxygen species. Nonethe-

Received February 14, 2011; accepted August 11, 2011.
From the Anesthesia Center for Critical Care Research of the Department of Anesthesia, Critical Care, and Pain Medicine (S.M., K.K., K.T., P.Y.S., S.K., E.S.B., K.D.B., F.I.), and Athinoula A. Martinos Center for Biomedical Imaging of the Department of Radiology (H.W., J.B.M., P.K.L., C.H.L.), Massachusetts General Hospital, Charlestown, and Department of Molecular Biomedical Research, VIB, and the Department of Medical Molecular Biology, Ghent University, Ghent, Belgium (P.B.).

*Drs. Minamishima and Kida contributed equally to this article.

The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.111.025395/-/DC1.

Correspondence to Fumito Ichinose, MD, PhD, Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, 149 13th St, 4315, Charlestown, MA 02129. E-mail fichinose@partners.org

© 2011 American Heart Association, Inc.

Circulation is available at http://circ.ahajournals.org

DOI: 10.1161/CIRCULATIONAHA.111.025395
less, the impact of endogenous and exogenous NO in the setting of CA/CPR, a whole-body IR injury complicated by systemic inflammation, is incompletely understood. In a previous study, we observed that deficiency of NOS3 or sGCα1 worsened outcomes of CA/CPR, whereas cardiomyocyte-specific overexpression of NOS3 rescued NOS3-deficient mice from myocardial and neurological dysfunction and death after CA.6 Along these lines, Dezfulian and colleagues7 recently reported that administration of nitrate at the initiation of CPR improved outcomes in a murine CA model, presumably by releasing NO. The protective effects of nitrate were associated with increased cardiac S-nitrosothiol levels and reversible inhibition of respiratory chain complex I in mitochondria. Although these results suggest that NO-dependent mechanisms have protective effects in CA/CPR, systemic administration of NO-donor compounds may induce systemic vasodilation and hypotension, frequently precluding its use in patients after CA in whom blood pressure may be low and unstable.

Although originally developed as a selective pulmonary vasodilator, inhaled NO has been shown to elicit systemic effects in a variety of preclinical and clinical studies without causing systemic vasodilation. For example, breathing NO attenuates myocardial IR injury in mice8 and swine,9 and hepatic IR injury in patients undergoing liver transplantation.10 On the basis of these observations, we hypothesized that NO inhalation could improve outcomes after CA/CPR. Here, we provide evidence that breathing NO starting 1 hour after CPR markedly improves neurological and myocardial function and 10-day survival rate in mice after CA.

Methods

Mice

After approval by the Massachusetts General Hospital Subcommittee on Research Animal Care, we studied 2- to 3-month-old age- and weight-matched male C57BL/6J wild-type (WT; n = 105), sGCα1-deficient (sGCα1−/−; n = 49,11) and NOS3-deficient (NOS3−/−, B6.129P2-Nos3tm1Unc/J; n = 33)12 mice on a C57BL/6J background. Because of their sensitivity to prolonged CA,6,14 NOS3−/− mice were subjected to CA for only 6.5 minutes. Subsequent procedures, including CPR, in NOS3−/− mice were conducted as described above.

Assessment of Neurological Function

Neurological function was assessed at 24 and 96 hours after CA/CPR or sham surgery with a previously reported neurological function scoring system.5,13,15 Briefly, 5 parameters were assessed and scored: level of consciousness (no reaction to pinching of tail = 0, poor response to tail pinch = 1, normal response to tail pinch = 2), corneal reflex (no blinking = 0, sluggish blinking = 1, normal blinking = 2), respirations (irregular breathing pattern = 0, decreased breathing frequency with normal pattern = 1, normal breathing frequency and pattern = 2), coordination (no movement = 0, moderate ataxia = 1, normal coordination = 2), and movement/activity (no spontaneous movement = 0, sluggish movement = 1, normal movement = 2). Total score was reported as the neurological function score (total possible score = 10).

Assessment of Right Ventricular Systolic Pressure

In a group of WT mice, right ventricular (RV) systolic pressure was measured 1 hour after CPR (before initiation of NO inhalation) or sham surgery with a conductance pressure-volume catheter (SPR839, Millar Instruments Inc, Houston, TX) inserted into the RV via the right jugular vein.

Effects of NO Inhalation on Myocardial Function

Left ventricular (LV) function was examined 4 days after CPR in WT mice that were subjected to CA/CPR and breathed air or air supplemented with NO or to sham surgery. Mice were anesthetized with fentanyl 250 μg/kg and ketamine 100 mg/kg IP, and LV function was measured with a conductance pressure-volume catheter, as previously described.16 Hemodynamic data were analyzed with a computer program (PVAN version 3.6, Millar Instruments).

Acquisition and Analysis of Magnetic Resonance Imaging

To investigate the degree of ischemic brain injury after CA/CPR, diffusion-weighted imaging (DWI) was performed 24 hours after CA/CPR in mice that breathed air (n = 6) or air supplemented with NO (n = 3) using standard magnetic resonance imaging acquisition and analysis methods as described previously (see the online-only Data Supplement for details).17 Apparent diffusion coefficient (ADC), calculated at each imaging voxel (3-dimensional volume element) from whole-brain images with 2 different diffusion weightings, reflects a single best measurement of the rate of water diffusion at that location. For quantitative analysis of the brain regions with abnormal water diffusion, average ADC values were calculated in anatomically distinct brain regions of interest determined from the Allen mouse brain atlas,18 including ventral lateral hippocampus, caudoputamen, lateral cortex, and whole brain. Average ADC values (μm²/ms) were computed in each mouse across each region of interest, and group average ADC values of mice that breathed air or NO were reported for each region of interest.

Measurement of Serum Nitrate/Nitrite Levels

Concentrations of nitrate and nitrite were measured in serum samples obtained at 24 hours after CA/CPR or sham surgery with a Nitrate/Nitrite Fluorometric Assay Kit (Cayman Chemical, Ann Arbor, MI) according to the manufacturer’s instructions.

Detailed descriptions of reagents and the protocol for quantitative real-time polymerase chain reaction and histological studies are provided in the Methods section in the online-only Data Supplement.

Statistical Analysis

All data are expressed as mean±SEM. Continuous data were analyzed with unpaired t tests, 2-way repeated measures ANOVA, or
Abnormality in the Brain 24 Hours After CA/CPR

Inhaled NO Prevents Water Diffusion Abnormality in the Brain 24 Hours After CA and CPR

Magnetic resonance imaging acquired 24 hours after CA/CPR in mice that breathed air showed areas of hyperintense DWI in the brain (Figure 2A). Hyperintense DWI signal (or reduced ADC signal) is a measure of brain edema presumably caused by disruption of ion pump homeostasis and membrane failure. Breathing NO for 23 hours starting 1 hour after CPR largely prevented the development of hyperintense DWI. The degree of abnormal water diffusion was quantified by calculating the average ADC in several regions of interest, including the ventral-lateral hippocampus, caudoputamen, and lateral-frontal cortex (Figure 2B). Breathing NO prevented the reduction of ADC values in each region of interest and across the whole brain (Figure 2C). These results suggest that breathing NO reduced the development of the ischemia-induced edema in the brain 24 hours after CA/CPR.

Inhaled NO Prevents Neurological Dysfunction 4 Days After CA and CPR

Although neurological function did not differ between surviving mice that breathed air and those that breathed NO at 1 day after CA/CPR, the neurological function score at 4 days after CA/CPR was better in surviving mice that breathed air supplemented with NO than in mice that breathed air alone ($P<0.01$; Figure 3A). These results suggest that breathing NO prevented the development of neurological dysfunction 4 days after CA/CPR in mice.

Inhaled NO Prevents Neuronal Apoptosis After CA and CPR

Histological studies revealed that the number of neurons containing activated caspase 3 in the CA1 region of the hippocampus was markedly increased at 4 days after CA/CPR in mice that breathed air (Figure 3B and 3C). Breathing NO starting 1 hour after CPR prevented caspase 3 activation in the hippocampal neurons. These results suggest that NO inhalation starting 1 hour after CPR prevents neuronal apoptosis in the brain.

Inhaled NO Prevents Myocardial Dysfunction After CA and CPR

There was no difference in heart rate and mean arterial pressure among mice at ROSC or 1 hour after CPR that were subsequently randomized to breathe air or air supplemented with NO (Table 1 in the online-only Data Supplement). Furthermore, there was no difference in RV systolic pressure at 1 hour after CPR between mice subjected to CA and mice subjected to sham operation, suggesting the absence of pulmonary hypertension after CA (data not shown).

Four days after CA/CPR, indexes of LV systolic and diastolic function, LV end-systolic pressure, LV end-diastolic pressure, maximum rate of developed LV pressure ($dP/dt_{max}$), minimum rate of developed LV pressure ($dP/dt_{min}$), cardiac output, arterial elastance, end-systolic elastance, end-diastolic elastance, preload-recruitable stroke work, and the time constant of isovolumic relaxation ($\tau$) were markedly impaired in mice that breathed air compared with sham-operated mice (the Table). Inhaled NO attenuated the impairment of heart rate, $dP/dt_{max}$, $dP/dt_{min}$, cardiac output, end-systolic elastance, end-diastolic elastance/arterial elastance, and $\tau$ at 4 days after CA/CPR. These results show that inhalation of NO for 23 hours starting 1 hour after CPR...
ameliorates post-CA myocardial dysfunction at 4 days after CA/CPR in mice. Inhaled NO Increased Serum Levels of Nitrite and Nitrate 24 Hours After CA/CPR

CA and CPR did not affect serum levels of nitrite and nitrate in mice that breathed air alone 24 hours after CA/CPR. Breathing air supplemented with NO for 23 hours markedly increased serum nitrite and nitrate levels compared with the levels in sham-operated mice (P<0.05 for nitrite and P<0.0001 for nitrate versus sham) and mice that breathed air alone after CPR (P<0.01 for nitrite and P<0.0001 for nitrate versus mice breathing air; Figure 4).

Deficiency of sGCα1, but Not NOS3, Abolishes the Salutary Effects of Inhaled NO on Survival Rate at 10 Days After CA/CPR

To elucidate the mechanisms responsible for the beneficial effects of NO inhalation on survival after CA/CPR, we examined whether inhaled NO improves outcomes of CA/CPR in sGCα1−/− mice.

Although ROSC was achieved in all 49 sGCα1−/− mice, 10 mice died soon after extubation and therefore were excluded from further analysis. The early mortality rate (in the first 2 hours after CPR) was higher in sGCα1−/− than in WT mice (3 of 105 WT mice died; P=0.0007 versus WT). In mice that survived long enough to be randomized to breathe air alone or air supplemented with NO for survival study (n=8 in each group), NO inhalation did not prevent neurological dysfunction on day 3 after CPR in sGCα1−/− mice (neurological function score 6±1 in mice that breathed air and 5±1 in mice that breathed NO; P=NS). Three of 8 sGCα1−/− mice that breathed air survived 10 days after CA/CPR. Inhalation of NO for 23 hours starting 1 hour after CPR did not improve the survival rate in sGCα1−/− mice (4 of 8 survived; Figure 5).

We considered the possibility that the reason for the failure of inhaled NO to improve the outcome in sGCα1−/− mice was that the injury induced by CA/CPR was too severe to be rescued by breathing NO. To test this hypothesis, we examined whether inhaled NO could improve outcomes in a strain of mice, NOS3−/− mice, that also manifest increased sensi-
Inhaled NO Prevents the Induction of Inflammatory Cytokines in WT but Not in sGCα1−/− Mice

Expression of genes encoding tumor necrosis factor-α, interleukin-6, interleukin-1β, and gp91phox (NOX2, a subunit of NADPH oxidase) was markedly greater in the brain cortex of WT mice that were subjected to CA/CPR and breathing air 24 hours after CA/CPR than in those of sham-operated mice (Figure 6). Breathing NO prevented the induction of tumor necrosis factor-α, interleukin-6, and NOX2 in the brain of WT mice subjected to CA/CPR.

Table. Left Ventricular Function 4 Days After Cardiac Arrest and Cardiopulmonary Resuscitation

<table>
<thead>
<tr>
<th></th>
<th>Sham (n=4)</th>
<th>Air (n=5)</th>
<th>iNO (n=5)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HR, bpm</strong></td>
<td>673 ± 7</td>
<td>482 ± 26*</td>
<td>591 ± 28†</td>
</tr>
<tr>
<td><strong>LVESP, mm Hg</strong></td>
<td>100 ± 6</td>
<td>58 ± 4*</td>
<td>73 ± 5*</td>
</tr>
<tr>
<td><strong>LVEDP, mm Hg</strong></td>
<td>2 ± 1</td>
<td>4 ± 1*</td>
<td>2 ± 0*</td>
</tr>
<tr>
<td><strong>dP/dtmax, mm Hg/s</strong></td>
<td>18.153 ± 1862</td>
<td>6159 ± 1007*</td>
<td>10461 ± 803†</td>
</tr>
<tr>
<td><strong>dP/dtmin, mm Hg/s</strong></td>
<td>-10599 ± 1189</td>
<td>-4235 ± 432*</td>
<td>-7248 ± 640†</td>
</tr>
<tr>
<td><strong>CO, mL/min</strong></td>
<td>12.4 ± 0.5</td>
<td>7.6 ± 1.0*</td>
<td>11.4 ± 0.6†</td>
</tr>
<tr>
<td><strong>dP/dtmax/IP, s⁻¹</strong></td>
<td>231 ± 9</td>
<td>198 ± 27</td>
<td>206 ± 18</td>
</tr>
<tr>
<td><strong>Ea, mm Hg/μL</strong></td>
<td>5 ± 0</td>
<td>4 ± 1*</td>
<td>4 ± 0*</td>
</tr>
<tr>
<td><strong>Ees, mm Hg/μL</strong></td>
<td>26 ± 5</td>
<td>6 ± 1*</td>
<td>15 ± 1†</td>
</tr>
<tr>
<td><strong>Ees/Ea</strong></td>
<td>4.7 ± 0.8</td>
<td>1.6 ± 0.3*</td>
<td>3.8 ± 0.1†</td>
</tr>
<tr>
<td><strong>PRSW, mm Hg</strong></td>
<td>141 ± 25</td>
<td>74 ± 9*</td>
<td>102 ± 11</td>
</tr>
<tr>
<td><strong>τ, ms</strong></td>
<td>4.9 ± 0.3</td>
<td>8.2 ± 0.6*</td>
<td>5.6 ± 0.4†</td>
</tr>
</tbody>
</table>

Sham indicates sham-operated mice; Air, mice that breathed air after cardiac arrest/cardiac pulmonary resuscitation; iNO, mice that breathed air supplemented with NO starting 1 hour after cardiac arrest/cardiac pulmonary resuscitation; HR, heart rate; LVESP, left ventricular end-systolic pressure; LVEDP, left ventricular end-diastolic pressure; dP/dtmax, maximum rate of developed left ventricular pressure; dP/dtmin, minimum rate of developed left ventricular pressure; CO, cardiac output; dP/dtmax/IP, dP/dtmax divided by instantaneous pressure; Ea, arterial elastance; Ees, left ventricular end-systolic elastance; PRSW, preload-recruitable stroke work; and τ, time constant of isovolumic relaxation. Values are mean ± SEM.

*P<0.05 vs Sham; †P<0.05 vs Air.
interleukin-1β, interleukin-6 (IL-6), IL-1β, and NOX2 gene expression in the brains of sGCα1−/− mice, the ability of NO inhalation to prevent the induction of these genes was abolished by sGCα1 deficiency (Figure II in the online-only Data Supplement). Taken together, these observations suggest that NO breathing exerts antiinflammatory and antioxidative effects in the brain after CA/CPR via sGC-dependent mechanisms.

Discussion

Although CA/CPR induced tumor necrosis factor-α, interleukin-1β, and NOX2 gene expression in the brains of sGCα1−/− mice, the ability of NO inhalation to prevent the induction of these genes was abolished by sGCα1 deficiency (Figure II in the online-only Data Supplement). Taken together, these observations suggest that NO breathing exerts antiinflammatory and antioxidative effects in the brain after CA/CPR via sGC-dependent mechanisms.

Figure 5. Survival rate of sGCα1−/− mice during the first 10 days after cardiac arrest and cardiopulmonary resuscitation (CA/CPR). Air sGCα1−/− indicates sGCα1−/− mice subjected to CA/CPR that breathed air; iNO sGCα1−/−, sGCα1−/− mice subjected to CA/CPR that breathed air supplemented with nitric oxide for 23 hours starting 1 hour after CPR. n=8 in each group. There was no difference in survival rates between the 2 groups.

Although CA/CPR induced tumor necrosis factor-α, interleukin-1β, and NOX2 gene expression in the brains of sGCα1−/− mice, the ability of NO inhalation to prevent the induction of these genes was abolished by sGCα1 deficiency (Figure II in the online-only Data Supplement). Taken together, these observations suggest that NO breathing exerts antiinflammatory and antioxidative effects in the brain after CA/CPR via sGC-dependent mechanisms.

Figure 6. Expression of genes encoding tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), IL-1β, and gp91phox (NOX2, a subunit of NADPH oxidase) in the brain cortex of wild-type mice 24 hours after sham surgery (Sham), after CA/CPR and breathing air (Air), or after CA/CPR and breathing air supplemented with NO (iNO) for 23 hours starting 1 hour after CPR. n=4 to 8. *P<0.05 vs Sham; #P<0.05 vs Air.

Figure 5. Survival rate of sGCα1−/− mice during the first 10 days after cardiac arrest and cardiopulmonary resuscitation (CA/CPR). Air sGCα1−/− indicates sGCα1−/− mice subjected to CA/CPR that breathed air; iNO sGCα1−/−, sGCα1−/− mice subjected to CA/CPR that breathed air supplemented with nitric oxide for 23 hours starting 1 hour after CPR. n=8 in each group. There was no difference in survival rates between the 2 groups.

Although CA/CPR induced tumor necrosis factor-α, interleukin-1β, and NOX2 gene expression in the brains of sGCα1−/− mice, the ability of NO inhalation to prevent the induction of these genes was abolished by sGCα1 deficiency (Figure II in the online-only Data Supplement). Taken together, these observations suggest that NO breathing exerts antiinflammatory and antioxidative effects in the brain after CA/CPR via sGC-dependent mechanisms.

Although CA/CPR induced tumor necrosis factor-α, interleukin-1β, and NOX2 gene expression in the brains of sGCα1−/− mice, the ability of NO inhalation to prevent the induction of these genes was abolished by sGCα1 deficiency (Figure II in the online-only Data Supplement). Taken together, these observations suggest that NO breathing exerts antiinflammatory and antioxidative effects in the brain after CA/CPR via sGC-dependent mechanisms.

Discussion

The present study demonstrates that NO inhalation at 40 ppm for 23 hours starting at 1 hour after successful CPR markedly improves myocardial and neurological function and survival rate at 10 days after CA/CPR in mice. The neuroprotective effects of inhaled NO were associated with attenuation of the severity of myocardial dysfunction correlates with poor neurological outcome.26 We found that the degree of LV

Although CA/CPR induced tumor necrosis factor-α, interleukin-1β, and NOX2 gene expression in the brains of sGCα1−/− mice, the ability of NO inhalation to prevent the induction of these genes was abolished by sGCα1 deficiency (Figure II in the online-only Data Supplement). Taken together, these observations suggest that NO breathing exerts antiinflammatory and antioxidative effects in the brain after CA/CPR via sGC-dependent mechanisms.

Although CA/CPR induced tumor necrosis factor-α, interleukin-1β, and NOX2 gene expression in the brains of sGCα1−/− mice, the ability of NO inhalation to prevent the induction of these genes was abolished by sGCα1 deficiency (Figure II in the online-only Data Supplement). Taken together, these observations suggest that NO breathing exerts antiinflammatory and antioxidative effects in the brain after CA/CPR via sGC-dependent mechanisms.

Although CA/CPR induced tumor necrosis factor-α, interleukin-1β, and NOX2 gene expression in the brains of sGCα1−/− mice, the ability of NO inhalation to prevent the induction of these genes was abolished by sGCα1 deficiency (Figure II in the online-only Data Supplement). Taken together, these observations suggest that NO breathing exerts antiinflammatory and antioxidative effects in the brain after CA/CPR via sGC-dependent mechanisms.
dysfunction 4 days after CPR was markedly attenuated in mice that breathed NO. These observations support the correlation between myocardial dysfunction and poor neurological outcomes and survival after CA/CPR.

RV dysfunction may also contribute to the circulatory failure after CA/CPR. Given the ability of inhaled NO to selectively reduce pulmonary artery pressure, it is conceivable that breathing NO improved outcomes of CA/CPR by reducing RV afterload. However, we did not find evidence of pulmonary hypertension in WT mice 1 hour after CA/CPR (before initiation of NO inhalation). Because inhaled NO reduces pulmonary artery pressure only in the presence of pulmonary hypertension, it is unlikely that inhaled NO improved outcomes after CA/CPR by reducing RV afterload in our model.

Neuroinflammation triggered by the whole-body IR injury associated with CA/CPR hinders the neurological recovery from prolonged CA. We observed that CA/CPR markedly upregulated the expression of genes encoding inflammatory cytokines and NADPH oxidase in the brain of WT mice that breathed air but not in WT mice that breathed air supplemented with NO. These observations suggest that NO inhalation prevents neuroinflammation after CA/CPR. Furthermore, these results demonstrate a correlation between neuroinflammation, neurological dysfunction, and mortality after CA/CPR.

NO elicits biological effects via sGC-dependent and/or-independent mechanisms. To determine the role of sGC in the protective effects of inhaled NO on the outcome of CA/CPR, we studied sGCα1−/− mice. We observed that sGCα1 deficiency increased the early mortality rate (in the first 2 hours after CPR) compared with WT mice after CA/CPR, consistent with our previous report. Although the cause of these early deaths is unknown, we previously reported that sGCα1 deficiency markedly exacerbated LV dysfunction early after CA/CPR. After the exclusion of mice that died early after CPR, sGCα1−/− mice that breathed air had a 10-day survival rate comparable to that in WT mice that breathed air after CA/CPR. These observations suggest that sGC activity is critically important for initial recovery after CA/CPR but may not be necessary for long-term survival after CA/CPR. In contrast, sGCα1 deficiency abolished the ability of NO inhalation to inhibit the induction of inflammatory cytokines in the brain and to improve neurological function and 10-day survival rate after CA. These observations suggest that protective effects of inhaled NO on the outcome of CA/CPR are mediated largely via sGC-dependent mechanisms.

Inhaled NO may exert systemic effects via interaction with circulating bone marrow–derived cells (eg, leukocytes) as they transit lungs. Alternatively, some NO, once inhaled, may escape scavenging by hemoglobin and be converted to relatively stable NO metabolites (eg, nitrite, S-nitrosothiols) that can regenerate NO in the periphery and directly protect neurons. In fact, in the present study, we found that breathing NO increased levels of nitrite and nitrate 24 hours after CA/CPR. We previously reported that neutrophils are required for inhaled NO to reduce myocardial infarction size in WT mice subjected to transient left coronary artery occlusion. Along these lines, we recently observed that breathing NO markedly decreased myocardial infarction size in WT but not in sGCα1−/− mice. Furthermore, breathing NO decreased myocardial infarction size in chimeric sGCα1−/− mice carrying WT bone marrow generated by bone marrow transplantation. These results raise the possibility that the neuroprotective effects of inhaled NO after CA/CPR may be mediated by bone marrow–derived cells in an sGC-dependent manner.

Our data do not exclude the possibility that sGC-independent mechanisms could contribute to the protective effects of inhaled NO on peripheral organs after CA/CPR. It is conceivable that NO modifies functions of enzymes and ion channels in an sGC-independent manner. For example, ischemic preconditioning has been shown to protect cardiomyocytes from subsequent IR injury by preventing Ca2+ overload via S-nitrosylation–mediated inhibition of L-type Ca2+ channel α1 subunit. Further studies are warranted to elucidate the mechanisms responsible for the protective effects of inhaled NO on outcome after CA/CPR. From the viewpoint of translating the present results into clinical benefit, it is of particular importance that NO inhalation started 1 hour after successful CPR and continued for 23 hours markedly improves neurological and myocardial function and survival rate 10 days after CA/CPR. For example, NO inhalation can be started after patients are transferred to hospital and informed consent is obtained. To date, therapeutic hypothermia is the only therapeutic approach proven to improve outcomes after CA/CPR when applied hours after successful CPR. Because the body temperature of mice was allowed to decrease to ~30°C during NO inhalation in the first 24 hours after CA/CPR in the present study, our data suggest that NO breathing may confer protection in the setting of mild hypothermia. Nonetheless, the effects of the combination of inhaled NO and therapeutic hypothermia, compared with either alone, on outcomes after CA/CPR remain to be formally determined in future studies.

This study has several limitations. The induction of CA by bolus administration of potassium chloride may have limited clinical relevance. However, we believe this model provides a valuable platform for elucidating the molecular mechanisms of organ dysfunction associated with CA/CPR and the impact of inhaled NO on the post-CA syndrome. All mice were anesthetized when subjected to CA/CPR. It is possible that drugs used to induce anesthesia may affect the outcomes of CA/CPR.

Conclusions

The present study revealed robust protective effects of NO inhalation on the outcome of CA/CPR in mice. Breathing NO at 40 ppm for 23 hours starting 1 hour after successful CPR markedly improved myocardial and neurological function and survival rate 10 days after CA/CPR, at least in part, via sGC-dependent mechanisms. The ability of delayed NO breathing to prevent post-CA brain injury and to promote survival in mice, if extrapolated to human beings, is highly clinically relevant and may serve as the experimental basis for future clinical trials in which the effects of inhaled NO on outcome after CA/CPR are examined. We anticipate that the
established safety profile of NO inhalation\(^3\) will enable the rapid translation of findings in animal models to patients suffering from the post-CA syndrome.

Acknowledgments
We wish to thank Dr Warren M. Zapol for valuable comments.

Sources of Funding
This work was supported by funding from the Jikei University School of Medicine (Dr Kida); Resuscitation Fellowship Award 09POST2220133 from the American Heart Association and Phillips (Dr Sips); AHA scientist development grant 10SDG2610313 (Dr Buys); AHA grant-in-aid GIA0855887D (Dr Liu); National Institutes of Health R01 grants DA26108 (Dr Liu), GM79360 (Dr Ichinose), and HL10930 (Dr Ichinose); and a sponsored research agreement between MGH and IKARIA Inc (Dr Bloch).

Disclosures
Drs Bloch and Ichinose have obtained patents relating to the use of inhaled NO. These patents are assigned to Massachusetts General Hospital, which has licensed them to IKARIA and Linde Gas Therapeutics, Lidingo, Sweden. The other authors report no conflicts.

References
5. Nishida T, Yu JD, Minamishima S, Sips PY, Searles RJ, Buys ES, Neilan TG, Furutani EM, Morgan JG, Janssens S. Nitric oxide inhalation33 will enable the rapid translation of findings in animal models to patients suffering from the post-CA syndrome.

5. Nishida T, Yu JD, Minamishima S, Sips PY, Searles RJ, Buys ES, Neilan TG, Furutani EM, Morgan JG, Janssens S. Nitric oxide inhalation33 will enable the rapid translation of findings in animal models to patients suffering from the post-CA syndrome.

5. Nishida T, Yu JD, Minamishima S, Sips PY, Searles RJ, Buys ES, Neilan TG, Furutani EM, Morgan JG, Janssens S. Nitric oxide inhalation33 will enable the rapid translation of findings in animal models to patients suffering from the post-CA syndrome.


---

**CLINICAL PERSPECTIVE**

Sudden cardiac arrest is one of the leading causes of death worldwide. Despite advances in resuscitation techniques, <8% of the 300,000 adults who experience cardiac arrest in the United States each year survive to hospital discharge, and up to 60% of survivors have long-lasting neurological deficits. Although therapeutic hypothermia has proven effective in clinical studies, no pharmacological agent is available to improve outcome from cardiac arrest. Although originally developed as a selective pulmonary vasodilator, inhaled nitric oxide (NO) has been shown to have systemic effects in a variety of preclinical and clinical studies without causing systemic vasodilation. In the present study, we found that breathing a low concentration of NO starting 1 hour after successful cardiopulmonary resuscitation for 23 hours markedly improves long-term neurological and cardiac outcomes and survival in mice subjected to cardiac arrest and cardiopulmonary resuscitation. The ability of NO breathing to improve outcomes after cardiac arrest when begun after cardiopulmonary resuscitation, if extrapolated to human beings, makes inhaled NO a practical therapeutic approach that can be initiated after patients are transferred to a hospital. Furthermore, because inhaled NO does not cause systemic hypotension, in contrast to systemic NO donors, it is uniquely suited for the treatment of post–cardiac arrest patients in whom blood pressure is often unstable. We anticipate that the established safety profile of NO inhalation will enable the rapid translation of findings in animal models to patients suffering from the post–cardiac arrest syndrome.
Inhaled Nitric Oxide Improves Outcomes After Successful Cardiopulmonary Resuscitation in Mice

Shizuka Minamishima, Kotaro Kida, Kentaro Tokuda, Huifang Wang, Patrick Y. Sips, Shizuko Kosugi, Joseph B. Mandeville, Emmanuel S. Buys, Peter Brouckaert, Philip K. Liu, Christina H. Liu, Kenneth D. Bloch and Fumito Ichinose

_Circulation_. published online September 19, 2011;

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/early/2011/09/19/CIRCULATIONAHA.111.025395

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2011/09/18/CIRCULATIONAHA.111.025395.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org/subscriptions/
SUPPLEMENTAL MATERIAL for “Inhaled Nitric Oxide Improves Outcome After Successful Cardiopulmonary Resuscitation in Mice.”

Shizuka Minamishima, MD\(^1\), Kotaro Kida, MD, PhD\(^1\), Kentaro Tokuda, MD\(^1\), Huifang Wang, PhD\(^2\), Patrick Y. Sips, PhD\(^1\), Shizuko Kosugi, MD\(^1\), Joseph B. Mandeville, PhD\(^2\), Emmanuel S. Buys, PhD\(^1\), Peter Brouckaert, MD, PhD\(^3,4\), Philip K. Liu, PhD\(^2\), Christina H. Liu, PhD\(^2\), Kenneth D. Bloch, MD\(^1\), Fumito Ichinose, MD, PhD\(^1\)

From \(^1\)the Anesthesia Center for Critical Care Research of the Department of Anesthesia, Critical Care, and Pain Medicine, and \(^2\)the Athinoula A. Martinos Center for Biomedical Imaging of the Department of Radiology, Massachusetts General Hospital, Charlestown, MA; \(^3\)the Department of Molecular Biomedical Research, VIB, and \(^4\)the Department of Medical Molecular Biology, Ghent University, Ghent, Belgium

**Supplemental Methods**

**MRI Acquisition**—Magnetic resonance imaging data were obtained using a 9.4 Tesla horizontal-bore magnet (Bruker Biospin Corp., Billerica MA) equipped with a custom surface coil for transmission and reception of radio frequencies for MRI of mouse brain. During imaging, mice were anesthetized by 2% isoflurane administered through a nose cone. Following image localization, multi-slice diffusion-weighted images (DWI) were acquired using a conventional spin-echo pulse sequence with an echo time of 26 ms, a
repetition time of one second, sixteen contiguous slices of 750 microns, and an isotropic resolution of 260 microns in the image plane. Two coronal diffusion weightings ("b values" of 154 and 1294 sec/mm²) were acquired every three minutes, and six pairs of diffusion values were acquired for each animal in order to reduce motion artifacts (e.g., due to respiration) by averaging.

MRI Analysis—For each animal, volumetric MRI data were aligned to the coordinate space of the Allen Mouse Brain atlas¹ using publicly available software developed by one of the authors (JBM: www.nitrc.org/projects/jip). Briefly, digitized slides of the Allen Mouse Brain “Reference Atlas” were segmented manually into gray matter, white matter, and cerebrospinal fluid in order to form a template for automated alignment of T2-weighted MR brain images from a cohort of mice. Subsequently, data from each animal were aligned to this cross-subject MRI template using automated adjustment of linear and non-linear transformations. Linear “affine” alignment (6-parameter rigid-body transformation plus 3 uniform inflations and 3 uniform skews) was followed by adjustment of three-dimensional distortion fields to reduce residual alignment errors due to MRI artifact or anatomical variance. All MRI data were registered into brain volumes with a slice thickness of 500 microns and an in-plane resolution of 250 microns.

Because DWI is sensitive to motion, respiration produced subtle artifacts in images with heavy diffusion weighting. To minimize these artifacts, each series of six b-values were averaged using a weighting function equal to the inverse of the global residue with respect to mean in order to produce a single time-averaged brain volume for each b-value. Subsequently, the apparent diffusion coefficient (ADC) for each brain
voxel was computed using the standard formulation for the MRI signal: \( S = S_0 \exp(-b \times \text{ADC}) \). Brains maps of average ADC were computed for each subject group, and the average ADC value within each region of interest was computed for each animal for entry into histograms and statistical tables.

**MRI Regions of Interest**—Anatomical regions of interest were determined by the Allen Brain Atlas and cross-subject maps of average ADC value in the two subject groups. These regions included (1) whole brain, (2) whole caudoputamen (blue outline in Supplemental Figure 1), and (3) whole hippocampus, as defined from the Allen Brain Atlas. Based on our pilot studies, two additional bilaterally symmetric regions of interest were defined: (1) lateral cortex (red outlines in Supplemental Figure 1) and (2) ventral lateral hippocampus (green outlines in Supplemental Figure 1).

**Histological studies**—Four days after CA/CPR, mice were sacrificed, and brains were perfusion-fixed in 4% formalin in PBS and embedded in paraffin. Brains were cut with a microtome in coronal planes including the hippocampus (6 \( \mu \text{m} \) thickness). Activation of caspase 3 was assessed by immunohistochemistry in paraffin-embedded brain sections obtained 96h after CA/CPR using a rabbit monoclonal antibody against cleaved caspase 3 (1:80, Cell Signaling) according to the protocol recommended by the manufacturer. Cleaved caspase 3-positive neurons in the CA1 sector of the hippocampus were manually counted by an investigator blinded to the treatment group, and the number of these neurons per square millimeter of examined area was reported.
**Measurements of gene expression**—Total RNA was extracted from cortex of mice 24h after CA/CPR or sham surgery using the illustra RNA spin Mini kit (GE Healthcare, Waukesha, WI), and cDNA was synthesized using MMLV-RT (Promega, Madison, WI). Tumor necrosis factor-α (TNF-α), Interleukin-1β (IL-1β), Interleukin-6 (IL-6), gp91phox (NOX2), and 18S ribosomal RNA transcript levels were measured by real-time PCR using a Realplex 2 system (Eppendorf, Westbury, NY). The following primer sets were used: TNF-α (5'-CAGCCTCTTTCTTCATGC-3', 5'-GGTCTGGGCCATAGAATGA-3'), IL-1β (TaqMan, Applied Biosystems), IL-6 (5'-CCGGAGAGAAGACTTCTCACAGA-3', 5'-CAGAATTGCCATTGCAACAAC-3'), NOX2 (5'-CTGCTCTCTTTCTCAGGGGT-3', 5'-GTGTGCAGTGGCTATCATA-3'), and 18S rRNA (5'-CGGCTACCACATCCAAGGAA-3', 5'-GCTGGAATTACCGCGGCT-3'). Changes in the relative gene expression normalized to levels of 18S rRNA were determined using the relative CT method. The mean value of samples from control mice was set as 1.
**Supplemental Table 1.** Group characteristics before cardiac arrest and in the first hour after cardiac arrest and CPR

<table>
<thead>
<tr>
<th></th>
<th>Air</th>
<th>Inhaled NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n=13)</td>
<td>(n=13)</td>
<td></td>
</tr>
<tr>
<td>Weight, g</td>
<td>24.6±0.5</td>
<td>24.3±0.4</td>
</tr>
<tr>
<td>HR before CA, bpm</td>
<td>594±18</td>
<td>587±11</td>
</tr>
<tr>
<td>MAP before CA, mmHg</td>
<td>123±3</td>
<td>123±3</td>
</tr>
<tr>
<td>Total dose of Epinephrine, µg</td>
<td>0.9±0.1</td>
<td>0.8±0.0</td>
</tr>
<tr>
<td>CPR time to ROSC, s</td>
<td>262±16</td>
<td>255±14</td>
</tr>
<tr>
<td>HR at ROSC, bpm</td>
<td>523±5</td>
<td>512±3</td>
</tr>
<tr>
<td>MAP at ROSC, mmHg</td>
<td>106±7</td>
<td>111±8</td>
</tr>
<tr>
<td>HR at 60 min after CPR, bpm</td>
<td>323±18</td>
<td>294±12</td>
</tr>
<tr>
<td>MAP at 60min after CPR, mmHg</td>
<td>49±3</td>
<td>48±2</td>
</tr>
</tbody>
</table>

Values are mean±SEM. Air, mice subjected to cardiac arrest and CPR that breathed air; Inhaled NO, mice subjected to cardiac arrest and CPR that breathed NO; CA, cardiac arrest; HR, heart rate; MAP, mean arterial pressure; CPR, cardiopulmonary resuscitation; ROSC, return of spontaneous circulation. No differences were found statistically significant.
Supplemental Figures and Figure legends

**Supplemental Figure 1.** Representative fast spin-echo images derived from the mouse showing the definition of the regions employed for analysis. Slices are labeled with respect to bregma in the coordinate space of the Allen Mouse Brain Atlas. Using the nomenclature employed in the manuscript, colored outlines identify caudoputamen (blue), lateral cortex (red), and ventral lateral hippocampus (green).
Supplemental Figure 2. Expression of genes encoding tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β, and gp91phox (NOX2, a subunit of NADPH oxidase) in the brain cortex of sGCα1−/− mice 24h after sham surgery (Sham), after CA/CPR and breathing air (Air), or after CA/CPR and breathing NO (iNO) starting 1h after CPR for 23h. N=4-8. *P<0.05 vs Sham.
Supplemental References